Al­ny­lam’s RNAi ther­a­py pass­es sec­ond Phase 2 hy­per­ten­sion test, with third un­der­way: #ACC24

Al­ny­lam’s RNAi can­di­date suc­cess­ful­ly re­duced 24-hour sys­tolic blood pres­sure in pa­tients with un­con­trolled hy­per­ten­sion when added to stan­dard of care in a mid-stage tri­al, re­in­forc­ing plans for a Phase 3 that will start once a sep­a­rate, on­go­ing Phase 2 test is com­plet­ed.

The drug, dubbed zilebe­sir­an, in­hibits the syn­the­sis of an­giotensino­gen (AGT) in the liv­er. AGT is the most up­stream pre­cur­sor of the renin-an­giotensin-al­dos­terone sys­tem (RAAS) cas­cade, which plays a key role in blood pres­sure reg­u­la­tion, ac­cord­ing to an Al­ny­lam re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER